Cart
sales@molnova.com
Orforglipron
CAS No. 2212020-52-3
Orforglipron( —— )
Catalog No. M32937 CAS No. 2212020-52-3
Orforglipron (LY3502970; GLP-1 receptor agonist 1) is an orally available glucagon-like peptide (GLP-1) receptor agonist for the study of obesity and type 1 diabetes in adults.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 389 | In Stock |
|
| 5MG | 597 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1822 | In Stock |
|
| 50MG | 2512 | In Stock |
|
| 100MG | 3321 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOrforglipron
-
NoteResearch use only, not for human use.
-
Brief DescriptionOrforglipron (LY3502970; GLP-1 receptor agonist 1) is an orally available glucagon-like peptide (GLP-1) receptor agonist for the study of obesity and type 1 diabetes in adults.
-
DescriptionOrforglipron (LY3502970) (GLP-1 receptor agonist 1) is a GLP-1 receptor agonist extracted from patent WO2018056453A1, Compound 67.
-
In VitroOrforglipron is an incretin secreted from L cells of the small intestine when nutrients pass through the digestive tract, and glucose is transmitted via the GLP-1 receptor. Orforglipron exhibits various actions such as dependent gastric emptying delay, and feeding suppression.
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2212020-52-3
-
Formula Weight882.96
-
Molecular FormulaC48H48F2N10O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (113.26 mM; Ultrasonic (<60°C)
-
SMILES[H][C@@]1(CCOC(C)(C)C1)c1ccc2n(c(cc2c1)C(=O)N1CCc2nn(c(c2[C@@H]1C)-n1ccn(-c2ccc3n(C)ncc3c2F)c1=O)-c1cc(C)c(F)c(C)c1)[C@]1(C[C@@H]1C)c1noc(=O)[nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Bay 55-9837
Selective VPAC2 receptor agonist (EC50 values are 0.4, 100 and >1000 nM for VPAC2, VPAC1 and PAC1, respectively in a cAMP accumulation assay; IC50 values are 60, 8700 and >10000 nM for VPAC2, VPAC1 and PAC1, respectively in a competition binding assay). Stimulates glucose-dependent insulin secretion in isolated human pancreatic islets. Reduces HIV-1 viral replication and shows cooperative effects when given in conjunction with VPAC1 agonists.
-
PF-06882961
PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06882961 shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat.
-
Apraglutide
Apraglutide (FE 203799 is a synthetic 33-amino acid peptide and long-acting glp-2 analogue.
